OKYO Pharma Limited (NASDAQ:OKYO - Get Free Report) shares shot up 0.5% during mid-day trading on Monday . The stock traded as high as $1.95 and last traded at $1.85. 2,459,157 shares traded hands during mid-day trading, an increase of 1,766% from the average session volume of 131,758 shares. The stock had previously closed at $1.84.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of OKYO Pharma in a report on Monday, May 5th.
Get Our Latest Analysis on OKYO
OKYO Pharma Stock Performance
The firm's 50 day moving average is $1.40 and its 200 day moving average is $1.23.
Institutional Investors Weigh In On OKYO Pharma
A hedge fund recently bought a new stake in OKYO Pharma stock. Dauntless Investment Group LLC acquired a new stake in OKYO Pharma Limited (NASDAQ:OKYO - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,988,780 shares of the company's stock, valued at approximately $2,526,000. OKYO Pharma comprises about 3.0% of Dauntless Investment Group LLC's investment portfolio, making the stock its 2nd biggest position. Dauntless Investment Group LLC owned about 5.88% of OKYO Pharma as of its most recent SEC filing. 2.97% of the stock is currently owned by institutional investors.
OKYO Pharma Company Profile
(
Get Free Report)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Further Reading
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
